Search results
Results from the WOW.Com Content Network
Bone marrow suppression due to anti-cancer chemotherapy is much harder to treat and often involves hospital admission, strict infection control, and aggressive use of intravenous antibiotics at the first sign of infection. [7] G-CSF is used clinically (see Neutropenia) but tests in mice suggest it may lead to bone loss. [8] [9]
radiotherapy, which can cause skin reactions, enteritis, fibrosis, myelopathy, bone necrosis, neuropathy or plexopathy; chemotherapy, often associated with chemotherapy induced peripheral neuropathy, mucositis, joint pain, muscle pain, and abdominal pain due to diarrhea or constipation; hormone therapy, which sometimes causes pain flares;
Potentially painful cancer treatments include immunotherapy which may produce joint or muscle pain; radiotherapy, which can cause skin reactions, enteritis, fibrosis, myelopathy, bone necrosis, neuropathy or plexopathy; chemotherapy, often associated with mucositis, joint pain, muscle pain, peripheral neuropathy and abdominal pain due to ...
Commonly prescribed thyroid drug levothyroxine was linked with bone mass and bone density loss in a cohort of older adults in a recent study. ... This in turn causes the thyroid to produce T3 and ...
Hair loss (alopecia) can be caused by chemotherapy that kills rapidly dividing cells; other medications may cause hair to thin. These are most often temporary effects: hair usually starts to regrow a few weeks after the last treatment, but sometimes with a change in color, texture, thickness or style.
Treatment for bone cancer depends on the type a person has and how far in the body it has spread. Most people will undergo treatment to remove the section of cancerous bone, chemotherapy and ...
Osteolytic lesion at the bottom of the radius, diagnosed by a darker section that indicates a loss of bone density. An osteolytic lesion (from the Greek words for "bone" (ὀστέον), and "to unbind" (λύειν)) is a softened section of a patient's bone formed as a symptom of specific diseases, including breast cancer and multiple myeloma.
Other pre-existing bone-marrow disorders such as acquired aplastic anemia following immunosuppressive treatment and Fanconi anemia can evolve into MDS. [15] MDS is thought to arise from mutations in the multipotent bone-marrow stem cell, but the specific defects responsible for these diseases remain poorly understood.